Ten23 health, a CDMO that launched just six months ago, continues to expand (PDF) its manufacturing facility in Visp, Switzerland.
The contract drug manufacturer will add an additional 1,000 square meters of space at the site for visual inspection, cold storage, cleanroom and other services that include device assembly operations, labeling and secondary packaging, the company said. The cost of the project wasn’t disclosed.
The plant, which was acquired from swissfillon last October, offers sterile filling of biologics such as gene and cell therapies into prefilled syringes, cartridges and vials from 1-liter to 200-liter bulk batch size using a fully automated and flexible filling line. The site was originally owned by Elanco.
“This first expansion … is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients,” Hanns-Christian Mahler, ten23’s chief executive, said in a statement.
Ten23 debuted in September 2021 and was financed by 3i Group of London, with its sights set on supporting biotech startups and established pharmaceutical customers for the development of injectables.